As of now all these drugs, which are appetite suppressants, are being dosed as you'll be on them for your lifetime. Maybe the dosing will be reduced but that hasn't been studied.
Dose reduction is a first step, but what’s needed is a protocol for stopping treatment while maintaining the reduced weight.
Companies such as LLY and NVO have a financial incentive to not develop a treatment-stopping protocol, but in due course they will be required to do so, IMO. Otherwise, the situation is untenable for the reasons you cited in #msg-173027522.